Combined molecular and clinical assessment of Plasmodium falciparum antimalarial drug resistance in the Lao People's Democratic Republic (Laos)

American Journal of Tropical Medicine and Hygiene

Volumn 77, Issue 1, 2007, Pages 36-43

  Mayxay, Mayfong ^a,b   Nair, Shalini ^c   Sudimack, Dan ^c   Imwong, Mallika ^d,e   Tanomsing, Naowarat ^d,e   Pongvongsa, Tiengkham ^f   Phompida, Samlane ^g   Phetsouvanh, Rattanaxay ^g   White, Nicholas J ^a,d,e,h   Anderson, Tim J C ^c   Newton, Paul N ^a,h  

^a MAHOSOT HOSPITAL   (Laos)

^b NATIONAL UNIVERSITY OF LAOS   (Laos)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Savannakhet Provincial Malaria Station ^*  (Thailand)

^f Savannakhet Provincial Malaria Station   (Laos)

^g Centre of Malariology   (Laos)

^h CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; CHLOROQUINE; FANSIDAR; MEFLOQUINE; PYRIMETHAMINE; ANTIMALARIAL AGENT; PROTOZOAL PROTEIN; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHLOROQUINE RESISTANCE TRANSPORTER GENE; CODON; CONFIDENCE INTERVAL; DIHYDROFOLATE REDUCTASE GENE; DIHYDROPTEROATE SYNTHASE GENE; DRUG DOSE REDUCTION; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENOTYPE; GEOGRAPHY; HUMAN; LAOS; MAJOR CLINICAL STUDY; MALARIA; MALE; MULTIVARIATE ANALYSIS; PLASMODIUM FALCIPARUM; RISK; TREATMENT FAILURE; ANIMAL; CLINICAL TRIAL; DRUG COMBINATION; DRUG RESISTANCE; GENETICS; ISOLATION AND PURIFICATION; MALARIA FALCIPARUM; MULTICENTER STUDY; MUTATION; PARASITOLOGY;

PLASMODIUM FALCIPARUM;

ADOLESCENT; ANIMALS; ANTIMALARIALS; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; LAOS; MALARIA, FALCIPARUM; MALE; MUTATION; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; PYRIMETHAMINE; SULFADOXINE;

EID: 34548754972     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2007.77.36     Document Type: Article

References (47)

1. White NJ, 2004. Antimalarial drug resistance. J Clin Invest 113: 1084-1092.
2. World Health Organization, 2005. Susceptibility of Plasmodium falciparum to Antimalarial Drugs: Report on Global Monitoring: 1996-2004. Geneva: World Health Organization, WHO/ HTM/MAL.1103. [Cited July 24, 2006]. Available from http:// whqlibdoc.who.int/wer/WHO_WER_2005/80_305_312
3. Bloland PB, Ettling M, 1999. Making malaria-treatment policy in the face of drug resistance. Ann Trop Med Parasitol 93: 5-23.
4. Baird JK, 2005. Effectiveness of antimalarial drugs. N Engl J Med 352: 1565-1577.
5. Djimde A, Doumbo OK, Steketee RW, Plowe CV, 2001. Application of a molecular marker for surveillance of chloroquine-resistance falciparum malaria. Lancet 358: 890-891.
6. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RAG, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185: 380-388.
7. Wang P, Brooks DR, Sims PF, Hyde JE, 1995. A mutation-specific PCR system to detect sequence variation in the dihydropteroate synthetase gene of Plasmodium falciparum. Mol Biochem Parasitol 71: 115-125.
8. Khan B, Omar S, Kanyara JN, Warren-Perry M, Nyalwidhe J, Peterson DS, Wellems T, Kaniaru S, Gitonga J, Mulaa FJ, Koech DK, 1997. Antifolate drug resistance and point mutations in Plasmodium falciparum in Kenya. Trans R Soc Trop Med Hyg 91: 456-460.
9. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkin WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK, 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 176: 1590-1596.
10. Kublin JG, Witzig RS, Shankar AH, Zurita JQ, Gilman RH, Guarda JA, Cortese JF, Plowe CV, 1998. Molecular assays for surveillance of antifolate-resistant malaria. Lancet 351: 1629-1630.
11. Jelinek T, Kilian AH, Kabagambe G, von Sonnenburg F, 1999. Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in Uganda: correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes. Am J Trop Med Hyg 61: 463-466.
12. Basco LK, Tahar R, Keundjian A, Ringwald P, 2000. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. J Infect Dis 182: 624-628.
13. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM, 2000. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 44: 991-996.
14. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, bir Singh Sidhu A, Naude B, Deitsch KW, Su X, Wootton JC, Roepe PD, Wellems TE, 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 6: 861-871.
15. Jelinek T, Aida AO, Peyerl-Hoffmann G, Jordan S, Mayor A, Heuschkel C, El Valy AO, Von Sonnenburg F, Christophel EM, 2002. Diagnostic value of molecular markers in chloroquine-resistant falciparum malaria in southern Mauritania. Am J Trop Med Hyg 67: 449-453.
16. Pillai DR, Labbe AC, Vanisaveth V, Hongvanthong B, Phompida S, Inthakone S, Zhong K, Kain KC, 2001. Plasmodium falciparum malaria in Laos: chloroquine treatment outcome and predictive value of molecular markers. J Infect Dis 183: 789-795.
17. Anderson TJ, Roper C, 2005. The origins and spread of antimalarial drug resistance: lessons for policy makers. Acta Trop 94: 269-280.
18. Ebisawa I, Muto T, Kameko S, Mitsui G, 1970. Response of Laotian malaria strains to chemotherapy. J Exp Med 40: 151-157.
19. Al-Tawil N, 1977. Response of falciparum malaria to a standard regimen of chloroquine in Vientiane, Lao People's Democratic Republic. J Trop Med Hyg 80: 230-237.
20. Al-Tawil N, 1978. Clearance of falciparum parasitemia with a single dose sulphadoxine-pyrimethamine in Vientiane, Laos. Southeast Asian J Trop Med Public Health 9: 409-413.
21. Guthmann JP, Kasparian S, Phetsouvanh R, Nathan N, Garcia M, Phompida S, Brockman A, Gastellu M, Legros D, 2002. The efficacy of chloroquine for the treatment of acute uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic. Ann Trop Med Parasitol 96: 553-557.
22. Mayxay M, Newton PN, Khanthavong M, Pongvongsa T, Phetsouvanh R, Phompida S, Brockman A, White NJ, 2003. Chloroquine versus sulphadoxine-pyrimethamine for treatment of Plasmodium falciparum malaria in Savannakhet province, Lao People's Democratic Republic: an assessment of national antimalarial drug recommendations. Clin Infect Dis 37: 1021-1028.
23. Mayxay M, Phetsouvanh R, Phompida S, Newton PN, Khanthavong M, Vannachone B, Brockman A, White NJ, 2003. A randomized comparison of oral chloroquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Laos. Trans R Soc Trop Med Hyg 97: 343-344.
24. Schwobel B, Jordan S, Vanisaveth V, Phetsouvanh R, Christophel EM, Phompida S, von Sonnenburg F, Jelinek T, 2003. Therapeutic efficacy of chloroquine plus sulphadoxine/ pyrimethamine compared with monotherapy with either chloroquine or pyrimethamine/sulphadoxine in uncomplicated Plasmodium falciparum malaria in Laos. Trop Med Int Health 8: 19-24.
25. Mayxay M, Khanthavong M, Lindegårdh N, Keola S, Barends M, Pongvongsa T, Yapom R, Annerberg A, Phompida S, Phetsouvanh R, White NJ, Newton PN, 2004. Randomized comparison of chloroquine plus sulphadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao PDR (Laos). Clin Infect Dis 39: 1139-1147.
26. Stohrer JM, Dittrich S, Thongpaseuth V, Vanisaveth V, Phetsouvanh R, Phompida S, Monti F, Christophel EM, Lindegårdh N, Annerbergerg A, Jelinek T, 2004. Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic. Trop Med Int Health 9: 1175-1183.
27. Sisouphanthong B, Taillard C, 2000. Atlas of Laos. Chiang Mai, Thailand: NIAS/Silkworm Books.
28. World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated falciparum Malaria. Geneva: World Health Organization, document no. WHO/HTM/RBM2003.50. [cited July 24, 2006]. Available from http://whqlibdoc.who.int/hq/2003/ WHO_HTM_RBM_2003.50.pdf
29. Nair S, Williams JT, Brockman A, Patphun L, Mayxay M, Newton PN, Guthmann JP, Smithuis FM, Hien TT, White NJ, Nosten F, Anderson TJ, 2003. A selective sweep driven by pyrimethamine treatment in southeast Asian malaria parasites. Mol Biol Evol 20: 1526-1536.
30. Nash D, Nair S, Mayxay M, Newton PN, Guthmann JP, Nosten F, Anderson T, 2005. Selection strength and hitchhiking around two anti-malarial resistance genes. Proc R Soc Lond B Biol Sci 272: 1153-1161.
31. Nair S, Brockman A, Paiphun L, Nosten F, Anderson TJC, 2002. Rapid genotyping of loci involved in antifolate drug resistance in Plasmodium falciparum by primer extension. Int J Parasitol 32: 852-858.
32. Anderson TJC, Nair S, Jacobzone C, Zavai A, Balkan S, 2003. Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazai Province, Sudan. Trop Med Int Health 8: 1068-1073.
33. Cockerham CC, Weir BS, 1984. Estimating F-statistics for the analysis of population structure. Evol Int J Org Evol 38: 1358-1370.
34. Schneider S, Roessli D, Excoffier L, 2000. Arlequin Version 2.000: A Software for Population Genetics Data Analysis. Geneva: Genetics and Biometry Laboratory, University of Geneva.
35. Goudet J, 2001. FSTAT, a Program to Estimate and Test Gene Diversities and Fixation Indices. Version 2.9.3. Available from http://www2.unil.ch/ popgen/softwares/fstat.htm
36. Zolg JW, Plitt JR, Chen GX, Palmer S, 1989. Point mutation in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol 36: 253-262.
37. Peterson DS, Milhous WK, Wellems TE, 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 87: 3018-3022.
38. Barens N, Schwoebel B, Jordan S, Vanisaveth V, Phetsouvanh R, Christophel EM, Phompida S, Jelinek T, 2003. Plasmodium falciparum: correlation of in vivo resistance to chloroquine and antifolates with genetic polymorphisms in isolates from the south of Lao PDR. Trop Med Int Health 8: 775-782.
39. Toma H, Imada Y, Vannachone B, Miyagi M, Kobayashi J, Uechi G, Pethuvang R, Manivong K, Phompida S, Sato Y, 2005. A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR. Southeast Asian J Trop Med Public Health 36: 602-604.
40. Khim N, Bouchier C, Ekala MT, Incardona S, Lim P, Legrand E, Jambou R, Doung S, Puijalon OM, Fandeur T, 2005. Countrywide survey shows very high prevalence of Plasmodium falciparum multilocus resistance genotypes in Cambodia. Antimicrob Agents Chemother 49: 3147-3152.
41. Huong NM, Davis TME, Cox-Singh J, Hewitt S, Toan TQ, Kim TB, Hanh NT, Phuong VN, Nhan DH, Cong LD, 2003. Treatment of uncomplicated falciparum malaria in southern Vietnam: can chloroquine or sulfadoxine-pyrimethamine be reintroduced in combination with artesunate? Clin Infect Dis 37: 1461-1466.
42. Lim P, Chy S, Ariey F, Incardona S, Chim P, Sem R, Denis MB, Hewitt S, Hoyer S, Socheat D, Puijalon-Merecreau O, Fandeur T, 2003. pfcrt polymorphism and chloroquine resistance in Plasmodium falciparum strains isolated in Cambodia. Antimicrob Agents Chemother 47: 87-94.
43. Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, Kawamoto F, Miller RS, Meshnick SR, 2003. Resistance to antimalarials in southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 47: 2418-2423.
44. Congpuong K, Na Bangchang K, Mungthin M, Bualombai P, Wernsdorfer WH, 2005. Molecular epidemiology of drug resistance markers of Plasmodium falciparum malaria in Thailand. Trop Med Int Health 10: 717-722.
45. Labbe AC, Bualombai P, Pillai DR, Zhong KJY, Vanisaveth V, Hongvanthong B, Looareesuwan S, Kain KC, 2001. Molecular markers for chloroquine-resistant Plasmodium falciparum malaria in Thailand and Laos. Ann Trop Med Parasitol 95: 781-788.
46. Dittrich S, Alifrangis M, Stohrer JM, Thongpaseuth V, Vanisaveth V, Phetsouvanh R, Phompida S, Khalil IF, Jelinek T, 2005. Falciparum malaria in the north of Laos: the occurrence and implications of the Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene haplotype SVMNT. Trop Med Int Health 10: 1267-1270.
47. World Health Organization, 2006. Guidelines for the Treatment of Malaria. Geneva: World Health Organization, WHO/HTM/ MAL 2006.1108. [cited July 24, 2006]. Available from http:// whqlibdoc.who.int/publication/2006/ 9241546948_eng.pdf